Clinical Trial: Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Brief Summary: This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.

Detailed Summary:
Sponsor: Poitiers University Hospital

Current Primary Outcome: Mean change from baseline in Best Corrected Visual Acuity (BCVA) [ Time Frame: 52 weeks ]

Mean change from baseline in Best Corrected Visual Acuity (BCVA) as measured by ETDRS letter score at 4 meters


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Poitiers University Hospital

Dates:
Date Received: December 10, 2014
Date Started: November 2014
Date Completion:
Last Updated: October 10, 2016
Last Verified: October 2016